DDInter493 DDInter1676
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Degarelix {u} (Compound) resembles {v} (Compound) Nafarelin
Degarelix {u} (Compound) resembles {v} (Compound) Cetrorelix
Degarelix {u} (Compound) treats {v} (Disease) prostate cancer
Degarelix {u} (Compound) binds {v} (Gene) GNRHR
Degarelix {u} (Compound) causes {v} (Side Effect) Urticaria
Degarelix {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tamoxifen
Degarelix {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Degarelix {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Degarelix (Compound) resembles Nafarelin (Compound)
Degarelix (Compound) resembles Cetrorelix (Compound)
Degarelix (Compound) treats prostate cancer (Disease)
Degarelix (Compound) binds GNRHR (Gene)
Degarelix (Compound) causes Urticaria (Side Effect)
Degarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Degarelix may lead to a major life threatening interaction when taken with Amiodarone
Degarelix may lead to a major life threatening interaction when taken with Ivabradine